

November 19, 2015

BIONIK

Bionik Laboratories to Present at the 8th Annual LD Micro Main Event on December 3, 2015

- Presentation with live webcast on Thursday, December 3rd at 12:00 p.m. PT -

TORONTO, Nov. 19, 2015 /PRNewswire/ -- [Bionik Laboratories Corp.](#) (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that it will present at the [8th Annual LD Micro Main Event](#) on Thursday, December 3, 2015, at 12:00 p.m. Pacific Time at the Luxe Sunset Hotel in Los Angeles, California.



BIONIK
LABORATORIES

[Peter Bloch, Chief Executive Officer](#) and Chairman of the Board, will provide a corporate overview and an update on the development progress of its primary product, [ARKE™, a robotic lower-body exoskeleton device](#) designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Mr. Bloch will also discuss the Company's plans to advance its growth strategy focused on acquiring, licensing and partnering synergistic products and technologies to supplement its internal product pipeline.

The Company recently [commenced production of the first rehabilitation units of ARKE GEN2](#), the second generation of its proprietary robotic device. Following assembly and production testing, Bionik expects to initiate shortly clinical testing with patients in Canadian rehabilitation centers and report initial findings from the use of ARKE by mid-2016.

A live webcast of the presentation will be available on Bionik's [IR Calendar](#) in the [Investor Relations](#) section of the Company's website (www.bioniklabs.com). The webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

About LD Micro

[LD Micro](#) is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The annual Main Event micro-cap conference was designed to highlight and showcase the next generation of great companies to private and institutional investors, as well as to analysts, bloggers, and the media. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor.

About Bionik Laboratories

Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton™ device that allows paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US\$13.1 million which enables the company to advance its development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired

results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Logo - <https://photos.prnewswire.com/prnh/20150817/258751LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/bionik-laboratories-to-present-at-the-8th-annual-ld-micro-main-event-on-december-3-2015-300181470.html>

SOURCE Bionik Laboratories Corp.